Arrowhead Pharmaceuticals, Inc.
ARWR
Classifica tra le azioni
#2402
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena,... Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Prezzo delle azioni
$58.99
Capitalizzazione di mercato
$8.33B
Variazione (1 giorno)
3.08%
Variazione (1 anno)
53.35%
Paese
US
Scambia Arrowhead Pharmaceuticals, Inc. (ARWR)
Categoria
Healthcare
Rapporto P/E per Arrowhead Pharmaceuticals, Inc. (ARWR)
Rapporto P/E al October 2026 TTM: -26.06
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Arrowhead Pharmaceuticals, Inc., il rapporto P/E attuale (TTM) è -26.06. Alla fine del 2024, il rapporto P/E era -3.87.
Storico del rapporto P/E per Arrowhead Pharmaceuticals, Inc. da 2000 a 2026
Rapporto P/E alla fine di ogni anno
| Anno | Rapporto P/E | Cambia |
|---|---|---|
| 2026 (TTM) | -26.06 | -99.08% |
| 2025 | -2.83K | 72,982.66% |
| 2024 | -3.87 | -72.45% |
| 2023 | -14.05 | -29.02% |
| 2022 | -19.79 | -56.96% |
| 2021 | -45.98 | -10.35% |
| 2020 | -51.29 | -231.83% |
| 2019 | 38.91 | -231.87% |
| 2018 | -29.51 | 220.29% |
| 2017 | -9.21 | 67.96% |
| 2016 | -5.49 | 52.64% |
| 2015 | -3.59 | -69.59% |
| 2014 | -11.82 | 169.96% |
| 2013 | -4.38 | 223.59% |
| 2012 | -1.35 | -84.87% |
| 2011 | -8.94 | -23.60% |
| 2010 | -11.70 | 652.11% |
| 2009 | -1.56 | 3.40% |
| 2008 | -1.50 | -74.89% |
| 2007 | -5.99 | -28.61% |
| 2006 | -8.39 | -24.21% |
| 2005 | -11.07 | -61.74% |
| 2004 | -28.95 | 5,729.12% |
| 2003 | -0.50 | 396.10% |
| 2002 | -0.10 | -84.00% |
| 2001 | -0.63 | -85.00% |
| 2000 | -4.17 | 0.00% |
Rapporto P/E per aziende simili o concorrenti
| Azienda | P/E Ratio | Differenza del P/E Ratio | Il paese |
|---|---|---|---|
| 28.78 | -210.45% |
US
|
|
| -28.36 | 8.83% |
US
|
|
| -24.57 | -5.72% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -216.39% |
NL
|
Come leggere un P/E ratio?
Il rapporto Prezzo/Utile (P/E) misura la relazione tra il prezzo delle azioni di una società e i suoi utili per azione.
Un P/E basso ma positivo indica un'azienda che genera alti profitti rispetto alla sua valutazione attuale e potrebbe essere sottovalutata. Un'azienda con un P/E negativo elevato (vicino allo 0) segnala forti perdite rispetto alla valutazione.
Le aziende con un P/E superiore a 30 o negativo sono generalmente considerate "azioni di crescita", cioè ci si aspetta che crescano o diventino redditizie.
Le aziende con un P/E positivo inferiore a 10 sono considerate "azioni di valore", ossia già molto redditizie ma con scarse prospettive di crescita.